Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced the successful completion of ...
Kynexis, a biotechnology company focused on precision therapeutics for brain diseases, launched today with €57 million in Series A financing led by Forbion, with participation from Ysios Capital and...
SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce the signing of an exclusive collaboration and licensing agre...
Tagworks Pharmaceuticals, the pioneer of Click-to-Release chemistry designed to deliver more effective and safer systemic therapies, today announced a $65 million Series A financing led by Ysios Capit...
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced th...
Minoryx is backed by a syndicate of experienced investors, which includes Columbus Venture Partners, CDTI Innvierte, Caixa Capital Risc, Fund+, Ysios Capital, Roche Venture Fund, Kurma Partners, Chies...
The round was led by RA Capital Management and Andera Partners. Additional new investors included RTW Investments, Rock Springs Capital, SR One Capital Management, Sectoral Asset Management, Ysios Cap...
The round was co-led by Columbus Venture Partners and Caixa Capital Risc. Dr. Damià Tormo, representing Columbus Venture Partners, has joined Minoryx’s Board of Directors. CDTI, through its Innvier...
The financing round was co-led by Ysios Capital and Forbion Growth and joined by new investors; a large managed care organization, and Hercules Capital, Inc. Existing investors Forbion Ventures, venBi...
Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472, further enhancing the company
Ysios Capital, a leading Spanish biotechnology venture capital firm, has announced that its portfolio company Aura Biosciences Inc. has priced its initial public offering (IPO) and is trading on the N...
Ysios Capital, a leading European venture capital firm specialized in the biotechnology sector, announces today that it has been successfully certified under the Diversity VC Standard, a certification...